3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
4
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Various Advanced Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Rituximab
131
Cyclophosphamide
74
fludarabine phosphate
51
Whole-Body Irradiation
38
Peripheral Blood Stem Cell Transplantation
36
Mycophenolic Acid
36
Tacrolimus
32
Etoposide
28
Busulfan
28
Melphalan
24
Lenalidomide
23
Prednisone
22
Filgrastim
22
Cyclosporine
22
Bortezomib
22
Antilymphocyte Serum
21
Vincristine
19
Methotrexate
19
obinutuzumab
17
Bendamustine Hydrochloride
16
fludarabine
15
Doxorubicin
15
Radiotherapy
14
ibrutinib
13
Dexamethasone
13
Cytarabine
13
Cord Blood Stem Cell Transplantation
13
Carmustine
13
pembrolizumab
12
idelalisib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Follicular
×
relatlimab
×
Clear all
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts